The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients
Open accessAbstract
Tumor-specific CD8+ T cells can potentially be activated by two distinct mechanisms of major histocompatibility complex class I–restricted antigen presentation as follows: direct presentation by tumor cells themselves or indirect presentation by professional antigen-presenting cells (APCs). However, controversy still exists as to whether indirect presentation (the cross-priming mechanism) can contribute to effective in vivo priming of tumor-specific CD8+ T cells that are capable of eradicating cancer in patients. A clinical trial of vaccination with granulocyte macrophage–colony stimulating factor–transduced pancreatic cancer lines was designed to test whether cross-presentation by locally recruited APCs can activate pancreatic tumor-specific CD8+ T cells. Previously, we reported postvaccination delayed-type hypersensitivity (DTH) responses to autologous tumor in 3 out of 14 treated patients. Mesothelin is an antigen demonstrated previously by gene expression profiling to be up-regulated in most pancreatic cancers. We report here the consistent induction of CD8+ T cell responses to multiple HLA-A2, A3, and A24-restricted mesothelin epitopes exclusively in the three patients with vaccine-induced DTH responses. Importantly, neither of the vaccinating pancreatic cancer cell lines expressed HLA-A2, A3, or A24. These results provide the first direct evidence that CD8 T cell responses can be generated via cross-presentation by an immunotherapy approach designed to recruit APCs to the vaccination site.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 2×
“cording to the following published sequences: M1 peptide (58–66) GILGFVFTL, derived from influenza matrix protein (29); mesothelin A2 (20–28) peptide SLLFLLFSL; mesothelin A2 (530–538) peptide VLPLTVAEV, identified using the available databases; and HIV-gag A2 peptide SLYNTVATL (75–83) (30), which contains an HLA-A2 b…”
MethodDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Self-citationDendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
Albert, M. L., Sauter, B., & Bhardwaj, N. (1998) · Nature · doi:10.1038/32183 · Cited by 2,349
SYFPEITHI: database for MHC ligands and peptide motifs
Rammensee, H. G., Bachmann, J., Emmerich, N. P. N., Bachor, O. A., & Stevanović, S. (1999) · Immunogenetics · doi:10.1007/s002510050595 · Cited by 2,314
Jung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Parker, K. C., Bednarek, M. A., & Coligan, J. E. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.1.163 · Cited by 1,370
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Antigen Recognition by Class I-Restricted T Lymphocytes
Townsend, A., & Bodmer, H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.003125 · Cited by 1,198
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Self-citationA Phagosome-to-Cytosol Pathway for Exogenous Antigens Presented on MHC Class I Molecules
Kovacsovics-Bankowski, M., & Rock, K. L. (1995) · Science · doi:10.1126/science.7809629 · Cited by 884
Cited by
Genetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Self-citationCarpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Maitra, A., & Hruban, R. H. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.154305 · Cited by 707
Self-citationLe, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
Self-citationCancer Immunotherapy Comes of Age
Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0899 · Cited by 586
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Lutz, E. R., Wu, A. A., Bigelow, E., Sharma, R., Mo, G., Soares, K., Solt, S., Dorman, A., Wamwea, A., Yager, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0027 · Cited by 550
Self-citationPancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i2.173 · Cited by 472
Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., & Linehan, D. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1746 · Cited by 450
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444
Eric, L., Yeo, C. J., Lillemoe, K. D., Biedrzycki, B., Kobrin, B., Herman, J., Sugar, E., Piantadosi, S., Cameron, J. L., Solt, S., et al. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3181fd271c · Cited by 403
Self-citationSoares, K. C., Rucki, A. A., Wu, A. A., Olino, K., Xiao, Q., Chai, Y., Wamwea, A., Bigelow, E., Lutz, E., Liu, L., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000062 · Cited by 398
Self-citationApoptotic Vesicles Crossprime CD8 T Cells and Protect against Tuberculosis
Winau, F., Weber, S., Sad, S., de Diego, J., Hoops, S. L., Breiden, B., Sandhoff, K., Brinkmann, V., Kaufmann, S. H. E., & Schaible, U. E. (2006) · Immunity · doi:10.1016/j.immuni.2005.12.001 · Cited by 395
Le, D. T., Brockstedt, D. G., Nir-Paz, R., Hampl, J., Mathur, S., Nemunaitis, J., Sterman, D. H., Hassan, R., Lutz, E., Moyer, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2121 · Cited by 369
Self-citationProstate cancer as a model for tumour immunotherapy
Drake, C. G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2817 · Cited by 347
Laheru, D., Lutz, E., Burke, J., Biedrzycki, B., Solt, S., Onners, B., Tartakovsky, I., Nemunaitis, J., Le, D., Sugar, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0371 · Cited by 346
Self-citationMesothelin targeted cancer immunotherapy
Hassan, R., & Ho, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.028 · Cited by 340
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan, R., Thomas, A., Alewine, C., Le, D. T., Jaffee, E. M., & Pastan, I. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.3672 · Cited by 325
Self-citationHassan, R., Remaley, A. T., Sampson, M. L., Zhang, J., Cox, D. D., Pingpank, J., Alexander, R., Willingham, M., Pastan, I., & Onda, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1477 · Cited by 296
Decreased Total Lymphocyte Counts in Pancreatic Cancer: An Index of Adverse Outcome
Fogar, P., Sperti, C., Basso, D., Sanzari, M. C., Greco, E., Davoli, C., Navaglia, F., Zambon, C.-F., Pasquali, C., Venza, E., et al. (2006) · Pancreas · doi:10.1097/01.mpa.0000188305.90290.50 · Cited by 260
Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Tamada, K., Geng, D., Sakoda, Y., Bansal, N., Srivastava, R., Li, Z., & Davila, E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1449 · Cited by 259
Molecular markers of early pancreatic cancer
Goggins, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.711 · Cited by 214
Self-citation
Metadata
- Authors
- Thomas, A. M., Santarsiero, L. M., Lutz, E. R., Armstrong, T. D., Chen, Y.-C., Huang, L.-Q., Laheru, D. A., Goggins, M., Hruban, R. H., & Jaffee, E. M.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2004-08-02
- Volume
- 200
- Issue
- 3
- Pages
- 297-306
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2106775454
- Cited by
- 347
- References
- 57
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.